Notably, following cytarabine therapy, residual cells showed increased FAO, increased CD36 expression, (a fatty acid translocase) and higher expression of an OXPHOS gene signature that is predictive of clinical response to treatment in PDX models and AML patients[33]. This evidence concerns the gene CD36 and acute myeloid leukemia.